Книги по разным темам Pages:     | 1 | 2 | 3 |

23. Duffy M. J., Duggan c. The urokinase plasminogen 3. PaX8-Peroxisome Proliferator-activated Receptor activator system: a rich source of tumour markers for the {gamma} (PPaR {gamma}) Dis-rupts Normal PaX8 or PPaR individualized management of patients with cancer // clin.

{gamma} Transcriptional Function and Stimulates Follicular Biochem. 2004. Vol. 37. P. 541 - 548.

Thyroid cell growth / a. y. au, c. McBride, K. g. wilhelm [et al.] // 24. Kushlinskij N. e. Klinicheskaja rolТ sistemy aktivacii endocrinology. 2006. Vol. 147. P. 367 - 376.

plazminogena v opuho-ljah cheloveka // Molekuljarnaja medicina.

4. a preoperative diagnostic test that distinguishes benign 2007. № 1. S. 4 - 8.

from malignant thyroid carci-noma based on gene expression / 25. The angiotensin I-converting enzyme gene J. M. cerutti, R. Delcelo, M. J. amadei [et al.] // J. clin. In-vest.

insertion/deletion polymorphism is linked to early gastric cancer / 2004. Vol. 113. P. 1234 - 1242.

M. P. ebert, u. Lendeckel, S. westphal [et al.] // cancer epidemiol.

5. Riesco-eizaquirre g., Santisteban P. Molecular biology of Biomarkers Prev. 2005. Vol. 14, № 12. P. 2987 - 1989.

thyroid cancer initiation // clin. Transl. Oncol. 2007. Vol. 9, № 11.

26. Rocken c., Lendeckel u., Dierkes J., westphal S. The P. 686 - 693.

number of lymph node metas-tases in gastric cancer correlates 6. Molecular>

with the angiotensin I-converting enzyme gene inser-tion/deletion distinct BRaF, RaS, and ReT/PTc mutation-specific gene polymorphism // clin. cancer Res. 2005. Vol. 1, № 11.

expression profiles discovered by DNa microarray analysis / P. 2526 - 2530.

T. J. giordano, R. Kuick, D. g. Thomas [et al.] // Oncogene. 2005.

27. angiotensin-converting enzyme gene insertion/deletion Vol. 24. P. 6646 - 6654.

polymorphism and breast can-cer risk // cancer epidemiol.

7. The ReT/PTc-RaS-BRaF linear signaling cascade Biomarkers Prev. 2005. Vol. 14, № 9. P. 2143 - 2146.

mediates the motile and mitogenic phenotype of thyroid cancer 28. Koh J. T., Biggins J. B. Ligand-receptor engineering cells / R. M. Melillo, M. D. castellone, V. guarino [et al.] // J. clin.

and its application towards the complementation of genetic Invest. 2005. Vol. 115. P. 1068 - 1081.

disease and target identification / a. M. gonzalez-Zuloeta Ladd, 8. Molecular pathology of well-differentiated thyroid a. a. Vasquez, F. a. Sayed-Tabatabaei [et al.] // curr. Top. Med.

carcinomas / M. Sobrinho-Simoes, a. Preto, a. S. Rocha [et al.] // chem. 2005. Vol. 5, № 4. P. 413 - 420.

Virchows arch. 2005. Vol. 447. P. 787 - 793.

29. angiotensin I-converting enzyme gene insertion/deletion 9. Prognostic factors in papillary thyroid cancer: an evaluation polymorphism and endome-trial human cancer in normotensive of 601 consecutive pa-tients / P. Siironen, J. Louhimo, S. Nordling and hypertensive women / M. Freitas-Silva, D. Pereira, c. coelho [et al.] // Tumour Biol. 2005. Vol. 26, № 2. P. 57 - 64.

[et al.] // cancer gene cytogenet. 2004. Vol. 155, № 1. P. 42 - 46.

10. Biological activity of activating thyroid-stimulating 30. chang H. S., Nam K. H., chung w. y., Park c. S. anaplastic hormone receptor mutants depends on the cellular context / thyroid carcinoma: a the-rapeutic dilemma // yonsei Med. J. 2005.

D. Fuhrer, M. D. Lewis, F. alkhafaji [et al.] // endocrinology. 2003.

Vol. 46, № 6. P. 759 - 764.

Vol. 144. P. 4018 - 4030.

31. angiotensin-converting enzyme gene insertion/deletion 11. Specific haplotypes of the ReT proto-oncogene are overpolymorphism is associated with risk of oral precancerous lesion represented in patients with sporadic papillary thyroid carcinoma in betel quid chewers / F. M. chung, y. H. yang, c. H. chen [et al.] / F. Lesueur, M. McKay, J. D. corbex [et al.] // J. Med. genet.

// Br. J. cancer. 2005. Vol. 93, № 5. P. 602 - 606.

2002. Vol. 39, № 4. P. 260 - 2655.

32. Martin M. D., Matrisian L. M. The other side of MMPs:

12. ReT/PTc and cK19 expression in papillary thyroid protective roles in tumor pro-gression // cancer Metastasis Rev.

carcinoma and its clinicopatho-logic correlation / w. y. chung, 2007. Vol. 26, № 3 - 4. P. 717 - 724.

e. Shin, w. I. yang [et al.] // J. Korean Med. Sci. 2005. Vol. 20, 33. Invasiveness of cutaneous malignant melanoma is № 1. P. 98 - 104.

influenced by matrix metalloprotei-nase 1 gene polymorphism / 13. High prevalence of BRaF mutations in thyroid cancer:

genetic evidence for constitu-tive activation of the ReT/PTc- S. ye, S. Dhillon, S. J. Turner [et al.] // cancer Res. 2001. Vol. 15, № 4. P. 1296 - 1298.

RaSBRaF signaling pathway in papillary thyroid carcinoma / 34. Pepper M. S. Lymphangiogenesis and tumor metastasis:

e. T. Kimura, M. N. Nikiforova, Z. Zhu [et al.] // cancer Res. 2003.

more questions than answers // Lymphology. 2000. Vol. 33, № 4.

Vol. 63. P. 1454 - 1457.

P. 144 - 147.

14. BRaF (V599e) mutation is the leading genetic event 35. Johansson N., ahonen M. Matrix metalloproteinases in in adult sporadic papillary thy-roid carcinomas / e. Puxeddu, tumor invasion // cell. Mol. Life Sci. 2000. Vol. 20, № 1. P. 5 - 15.

S. Moretti, R. elisei [et al.] // J. clin. endocrinol. Metab. 2004.

36. a single Nucleotide Polymorphism in the MMP-3 promoter Vol. 89, № 5. P. 2414 - 2420.

enhances breast cancer susceptibility / g. ghilardi, M. L. Biondi, 15. BRaF mutations are associated with some histologica l types of papillary thyroid car-cinoma / V. Trovisco, I. Vieira M. caputo [et al.] // cancer Res. 2002. Vol. 8. P. 3820 - 3823.

de castro, P. Soares [et al.] // J. Pathol. 2004. Vol. 202, № 2. 37. Bogusiewicz M., Stryjecka-Zimmer M., P. 247 - 251. Szymanski M. activity of matrix metallopro-teinases-2 and Ц16. Proximity of chromosomal loci that participate in radiation- in advanced laryngeal cancer // Otolaryngol. Head Neck. Surg.

induced rearrangements in human cells / M. N. Nikiforova, 2003. Vol. 128, № 1. P. 132 - 136.

J. R. Stringer, R. Blough [et al.] // Science. 2000. Vol. 290. 38. Shiomi T., Okada y. MMP-1 and MMP-7 in invasion and P. 138 - 141. metastasis of human cancers // cancer Metastasis Rev. 2003.

17. Proline homozygosity in codon 72 of p53 is a factor of Vol. 22. P. 145 - 152.

susceptibility for thyroid cancer / F. granja, J. Morari, e. c. Morari 39. Reichenberger F., eickelberg O., wyser c., [et al.] // cancer Lett. 2004. Vol. 16, № 210. P. 151 - 157. Perruchoud a. P. Distinct endobronchial expression of matrix18. gST profiling may be useful in the screening for thyroid metalloproteinases (MMP) and their endogenous inhibitors in lung nodule malignancy / F. gran-ja, J. Morari, e. c. Morari [et al.] // cancer // Swiss Med. wkly. 2001. Vol. 19, № 131. P. 273 - 279.

cancer Lett. 2004. Vol. 25, № 209. P. 129 - 137. 40. Bogatikov a. a. Prognosticheskoe znachenie kliniko19. Shi y. B, Fu L, Hasebe T., Ishizuya-Oka a. Regulation of geneticheskih faktorov v hirurgicheskom lechenii papilljarnogo extracellular matrix remode-ling and cell fate determination by raka witovidnoj zhelezy: avtoref. dis. Е kand. med. nauk. SPb., matrix metalloproteinase stromelysin-3 during thyroid hormone- 2010. 27 s.

Саратовский научно-медицинский журнал. 2012. Т. 8, № 3.

Pages:     | 1 | 2 | 3 |    Книги по разным темам